-- Robert Preidt
TUESDAY, May 1 (HealthDay News) -- A management plan to gather,
assess and respond to data about all medications' risks from the
time they are approved until they are no longer on the market is
needed to improve drug safety in the United States, says an
Institute of Medicine report released Tuesday.
The U.S. Food and Drug Administration approves new drugs based
on clinical trial evidence that their benefits outweigh their
risks. However, the full range of a medication's effects may not
become apparent until it is used by a larger, more diverse
population over a long period of time, the FDA-sponsored report
A number of drugs approved by the FDA were later found to have
problems, including the pain reliever Vioxx, the diabetes drug
Avandia and the cholesterol-lowering drug Crestor.
Report recommendations include:
"It is not possible to know what the full range of a drug's benefits and risks will be until it is used by many different kinds of patients over time, so it is critical that FDA continues to monitor and learn about the effects of drugs after they are marketed," said report committee co-chair Ruth Faden, a professor of biomedical ethics and executive director of the Berman Institute of Bioethics, Johns Hopkins University, said in an Institute of Medicine news release.
The FDA already gathers much of this information but it is
scattered across multiple records. Collecting this information in a
single, publicly accessible format would show the FDA's commitment
to this drug "life-cycle" approach and make the process more open,
according to the report.
Among its other recommendations, the report also said the FDA
should order postmarket studies only if: a regulatory decision
cannot be made based on existing safety evidence; the research can
sufficiently address concerns about a drug's benefit-risk balance
to help lead to a regulatory decision; the results will be used to
make a regulatory decision in a timely fashion; and the rights and
interests of the research participants can be adequately
In addition, the FDA should ensure that postmarket studies it
orders are conducted in ways that are ethically and scientifically
sound, the report said.
"Our report focuses on how the agency can be proactive so that situations in which a drug's benefit-risk profile becomes problematic can be detected earlier, and it details how FDA can get the additional information on a drug's safety in the most ethical and scientifically sound ways when questions arise," Faden noted in the news release.
Report committee co-chair Steven Goodman, associate dean for
clinical and translational research at Stanford University School
of Medicine, added: "We believe that the adoption of a life-cycle
approach to drug approval and monitoring will help the agency
strengthen its oversight, better tackle these complex decisions,
and increase public confidence in the agency's ability to protect
public health. This will become increasingly important as FDA looks
for ways to safely expedite the drug-approval process."
The U.S. Food and Drug Administration outlines how it manages
drug safety issues.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.